Nicotinamide adenine dinucleotide (NAD⁺) is a vital coenzyme that supports cellular energy metabolism and overall physiological function. As individuals age, NAD⁺ levels naturally diminish, a process associated with the onset of various age-related health conditions. To address this, NAD⁺ precursors like nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are being explored for therapeutic use. These compounds show promise in treating neurodegenerative and metabolic conditions, prompting increased pharmaceutical interest.¹ In 2024, the global market for NAD⁺ products was estimated at around USD 494 million, with forecasts suggesting it could rise to USD 873.4 million by 2031, reflecting an expected compound annual growth rate of 14%.
This article highlights key applications, clinical trial developments, and regulatory classifications of NAD⁺ and its derivatives across major global markets.
NAD⁺ and Neurodegenerative Disease Therapies
Declining NAD⁺ levels have been linked to brain aging and neurodegenerative disorders like Alzheimer’s and Parkinson’s. Boosting NAD⁺ may enhance mitochondrial function, support DNA repair, and activate neuroprotective pathways such as sirtuins.²
Several NAD⁺ precursors are under investigation. While high-dose nicotinamide showed limited results in Alzheimer’s trials, newer agents like nicotinamide riboside (NR) have demonstrated promising early outcomes in Parkinson’s. A Phase 1 trial (NADPARK) showed NR raised brain NAD⁺ levels and reduced neuroinflammation. A more extensive Phase 2 clinical trial, known as NOPARK, is currently in progress.
● In Alzheimer’s research, NMN-based therapies such as MIB-626 have shown the ability to cross the blood-brain barrier and elevate NAD⁺ in cerebrospinal fluid. Follow-up studies will evaluate clinical benefits on cognition and disease biomarkers.
● Although no NAD⁺ therapy has yet achieved clinical approval for neurodegeneration, growing evidence supports its potential as a disease-modifying approach.
NAD⁺ in Metabolic and Mitochondrial Health
NAD⁺ plays a vital role in energy metabolism, insulin sensitivity, and mitochondrial function.Reduced levels of NAD⁺ have been associated with metabolic disorders such as type 2 diabetes, non-alcoholic fatty liver disease, and mitochondrial dysfunction.
Clinical studies show that NAD⁺ precursors like NMN and nicotinamide can improve insulin sensitivity, reduce liver fat, and enhance metabolic profiles. In rare mitochondrial disorders, niacin supplementation has successfully restored NAD⁺ levels and improved muscle performance.
While results vary, ongoing trials suggest NAD⁺ boosters may help manage metabolic conditions and support mitochondrial health, especially in aging or insulin-resistant populations.³
NAD⁺ and Healthy Aging
Declining NAD⁺ levels are linked to aging-related issues like reduced energy, impaired DNA repair, and muscle weakness. NAD⁺ boosters such as NMN and NR are being studied for their potential to support longevity by improving mitochondrial function and reducing cellular aging.³
Clinical trials show these supplements can safely raise NAD⁺ levels in older adults. Early findings suggest benefits like improved muscle endurance, reduced fatigue, and better cardiovascular function.⁴ While “anti-aging” isn’t a recognized medical indication, NAD⁺ repletion is emerging as a promising strategy to target age-related decline.
Regulatory Status of NAD⁺ Compounds Across Major Markets
The classification of NAD⁺ and its precursors, including NR (nicotinamide riboside), NMN (nicotinamide mononucleotide), and NADH, differs considerably across countries. In certain regions, these compounds are permitted for use in dietary supplements or functional foods, whereas in others, they are regulated as novel ingredients or investigational substances.
United States (FDA)
In the U.S., NR is legally sold as a dietary supplement and has b...
(All Rights Reserved)